<DOC>
	<DOCNO>NCT00937495</DOCNO>
	<brief_summary>This phase II trial study well give vorinostat together bortezomib work treat patient advanced soft tissue sarcoma . Vorinostat bortezomib may stop growth tumor cell block enzymes need cell growth . Giving vorinostat together bortezomib may kill tumor cell .</brief_summary>
	<brief_title>Vorinostat Bortezomib Treating Patients With Advanced Soft Tissue Sarcoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine objective response rate patient advance soft tissue sarcoma treat vorinostat bortezomib . SECONDARY OBJECTIVES : I . Characterize toxicity regimen patient . II . Evaluate progression-free survival median overall survival patient treat regimen . OUTLINE : Patients receive vorinostat orally ( PO ) daily day 1-14 . Patients also receive bortezomib intravenously ( IV ) 3-5 second day 1 , 4 , 8 , 11 . Courses repeat every 21 day absence disease progression unacceptable toxicity . After completion study therapy , patient follow every 6 month 2 year . ( As Addendum 7 , patient follow-up longer require . )</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Histologically cytologically confirm advanced , unresectable , metastatic soft tissue sarcoma ( STS ) Measurable disease , define &gt; = 1 lesion accurately measure &gt; = 1 dimension &gt; = 2 cm conventional technique OR &gt; = 1 cm spiral compute tomography ( CT ) scan No small round cell tumor , include follow : Primitive neuroectodermal tumor Rhabdomyosarcoma Ewing sarcoma Osteosarcoma No known active and/or untreated brain metastasis and/or brain metastasis require ongoing therapy ( e.g. , corticosteroid ) Treated , inactive brain metastasis require ongoing therapy allow provide brain metastasis stable &gt; = 1 month assess intracranial imaging AND indication increase vascularity treat metastasis within 14 day study entry assess magnetic resonance imaging ( MRI ) Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 01 OR Karnofsky PS 70100 % Life expectancy &gt; = 12 week Absolute neutrophil count ( ANC ) &gt; = 1,500/mm^3 Platelet count &gt; = 100,000/mm^3 Total bilirubin normal Aspartate aminotransferase ( AST ) and/or alanine aminotransferase ( ALT ) = &lt; 2.5 time upper limit normal Creatinine normal OR creatinine clearance &gt; = 60 mL/min Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Able take oral medication No peripheral neuropathy &gt; = grade 2 No concurrent uncontrolled illness include , limited , follow : Ongoing active infection Symptomatic congestive heart failure Unstable angina pectoris Cardiac arrhythmia myocardial infarction within past 6 month Psychiatric illness and/or social situation would limit compliance study requirement No history Torsades de Pointes No history allergic reaction attribute compound similar chemical biological composition vorinostat bortezomib No 1 prior systemic treatment advanced STS , include investigational agent Adjuvant therapy consider systemic regimen More 2 week since prior valproic acid More 4 week since prior concurrent chemotherapy ( &gt; 6 week nitrosoureas mitomycin C ) radiotherapy recover Radiotherapy bone metastasis within past 2 week allow provide active nonbone disease outside radiation port No prior radiotherapy &gt; = 33 % bone marrow No prior vorinostat bortezomib No concurrent category I medication generally accept risk cause Torsades de Pointes , include follow : Quinidine , procainamide , disopyramide Amiodarone , sotalol , ibutilide , dofetilide Erythromycin , clarithromycin Chlorpromazine , haloperidol , mesoridazine , thioridazine , pimozide , cisapride , bepridil , droperidol , methadone , arsenic , chloroquine , domperidone , halofantrine , levomethadyl , pentamidine , sparfloxacin , lidoflazine No concurrent combination antiretroviral therapy human immunodeficiency virus ( HIV ) positive patient No concurrent investigational agent primary malignancy No concurrent anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>